ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 557

Inhibition of Calcium/Calmodulin-Dependent Protein Kinase 4 Ameliorates Th17 Related Autoimmune Disorder

Tomohiro Koga1, Christian Hedrich1, Masayuki Mizui2, Nobuya Yoshida3, Linda Lieberman4, José C. Crispin1 and George C. Tsokos5, 1Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Department of Medicine,, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 4Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 5Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: animal models and systemic lupus erythematosus (SLE), T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: IL-17-producing T helper (Th17) cells have been causally linked to tissue inflammation in several autoimmune diseases including lupus and multiple sclerosis. Blockade of Th17 action or differentiation could therefore represent a useful therapeutic strategy in these settings.

Methods: We immunized C57B/6 mice or Camk4 deficient C57B/6 (B6 Camk4-/-) mice with MOG 35-55 emulsified in complete Freund’s adjuvant (CFA) containing Mycobacterium tuberculosis and evaluated the disease activity. MRL/lpr mice were treated with KN-93, an antagonist of calcium/calmodulin-dependent protein kinase IV (CaMK4), and examined IL-17 producing T cell in the spleen and lymph node in vivo and in vitro. We also tested the number of infiltrated T cell and IL-17 related genes in lungs and kidneys. Furthermore, We compared the methylation status in Il2 or Il17A promoter and the binding capacity of cAMP response element modulator (CREM)-α to these promoters in Camk4 sufficient or deficetnt conditions. To determine the relevance of our findings to human SLE, we analyzed the effect of CaMK4 inhibition on Th17 cells function in T cells from patients.

Results: Here, we show that KN-93 inhibits Th17 cell differentiation both in vivo and in vitro. The relevance of this is reflected by the fact that B6 Camk4-/- mice suffer less experimental autoimmune encephalomyelitis (EAE) and MRL/lpr Camk4-/- have decreased autoimmunity and organ damage. Treatment of MRL/lpr mice with KN-93 decreases Th17 cell differentiation, prevents double negative T cells from infiltrating lungs and kidneys, and protects against organ damage. In in vitro experiments, KN-93 diminishes IL-17 production and reciprocally improves IL-2 production by CD4 T cells cultured under Th17-polarizing conditions. These effects are mediated through the activity of CREM-α that controls epigenetic remodeling of the Il2 and Il17a loci. Analogously, silencing of CaMK4 in T cells from patients with SLE and healthy controls decreases the expression of IL17A upon stimulation in the presence of TGF-β and IL-6. 

Conclusion:

Collectively, our results suggest that CaMK4 inhibition might be a promising therapeutic agent for autoimmune diseases mediated by Th17 cells.


Disclosure:

T. Koga,
None;

C. Hedrich,
None;

M. Mizui,
None;

N. Yoshida,
None;

L. Lieberman,
None;

J. C. Crispin,
None;

G. C. Tsokos,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-calciumcalmodulin-dependent-protein-kinase-4-ameliorates-th17-related-autoimmune-disorder/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology